A replicating adenovirus capsid display recombinant elicits antibodies against Plasmodium falciparum sporozoites in Aotus nancymaae monkeys

Infection and Immunity

Volumn 83, Issue 1, 2015, Pages 268-275

  Karen, Kasey A ^a,c   Deal, Cailin ^a,d   Adams, Robert J ^b   Nielsen, Carolyn ^a,e   Ward, Cameron ^a,f   Espinosa, Diego A ^a   Xie, Jane ^a   Zavala, Fidel ^a   Ketner, Gary ^a  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c GEORGIA COLLEGE AND STATE UNIVERSITY   (United States)

^d MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^e LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^f Sg2   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VACCINE; ANTIBODY; EPITOPE; GREEN FLUORESCENT PROTEIN; CIRCUMSPOROZOITE PROTEIN, PROTOZOAN; DRUG CARRIER; MALARIA VACCINE; NEUTRALIZING ANTIBODY; PROTOZOAL PROTEIN; PROTOZOON ANTIBODY; RECOMBINANT VACCINE;

ADENOVIRIDAE; ANIMAL EXPERIMENT; ANIMAL MODEL; AOTUS; AOTUS NANCYMAAE; ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN ADENOVIRUS; IMMUNIZATION; IMMUNOGENICITY; MALARIA; MALE; MOUSE; NONHUMAN; PLASMODIUM FALCIPARUM; SPOROZOITE; VIRUS CAPSID; VIRUS REPLICATION; ANIMAL; AOTIDAE; BLOOD; CELL SURFACE DISPLAY; GENE VECTOR; GENETICS; IMMUNOLOGY;

ADENOVIRIDAE; ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, PROTOZOAN; AOTIDAE; CELL SURFACE DISPLAY TECHNIQUES; DRUG CARRIERS; FEMALE; GENETIC VECTORS; MALARIA VACCINES; MALE; PLASMODIUM FALCIPARUM; PROTOZOAN PROTEINS; VACCINES, SYNTHETIC;

EID: 84919466451     PISSN: 00199567     EISSN: 10985522     Source Type: Journal    
DOI: 10.1128/IAI.02626-14     Document Type: Article

References (36)

1. Top FH, Jr, Buescher EL, Bancroft WH, Russell PK. 1971. Immunization with live types 7 and 4 adenovirus vaccines. II. Antibody response and protective effect against acute respiratory disease due to adenovirus type 7. J Infect Dis 124:155-160.
2. Top FH, Jr, Grossman RA, Bartelloni PJ, Segal HE, Dudding BA, Russell PK, Buescher EL. 1971. Immunization with live types 7 and 4 adenovirus vaccines. I. Safety, infectivity, antigenicity, and potency of adenovirus type 7 vaccine in humans. J Infect Dis 124:148-154. http://dx.doi.org/10.1093/infdis/124.2.148.
3. Gaydos CA, Gray GC. 2008. Adenovirus vaccine, p 1103-1122. In Plotkin SA, Orenstein MD (ed), Vaccines. Saunders, Philadelphia, PA.
4. Clyde DF, Most H, McCarthy VC, Vanderberg JP. 1973. Immunization of man against sporozoite-induced falciparum malaria. Am J Med Sci 266:169-177.
5. Seder RA, Chang LJ, Enama ME, Zephir KL, Sarwar UN, Gordon IJ, Holman LA, James ER, Billingsley PF, Gunasekera A, Richman A, Chakravarty S, Manoj A, Velmurugan S, Li M, Ruben AJ, Li T, Eappen AG, Stafford RE, Plummer SH, Hendel CS, Novik L, Costner PJ, Mendoza FH, Saunders JG, Nason MC, Richardson JH, Murphy J, Davidson SA, Richie TL, Sedegah M, Sutamihardja A, Fahle GA, Lyke KE, Laurens MB, Roederer M, Tewari K, Epstein JE, Sim BK, Ledgerwood JE, Graham BS, Hoffman SL. 2013. Protection against malaria by intravenous immunization with a nonreplicating sporozoite vaccine. Science 341:1359-1365. http://dx.doi.org/10.1126/science.1241800.
6. Sinnis P, Nardin E. 2002. Sporozoite antigens: biology and immunology of the circumsporozoite protein and thrombospondin-related anonymous protein. Chem Immunol. 80:70-96. http://dx.doi.org/10.1159/000058840.
7. Zavala F, Masuda A, Graves PM, Nussenzweig V, Nussenzweig RS. 1985. Ubiquity of the repetitive epitope of the CS protein in different isolates of human malaria parasites. J Immunol 135:2790-2793.
8. Zavala F, Cochrane AH, Nardin EH, Nussenzweig RS, Nussenzweig V. 1983. Circumsporozoite proteins of malaria parasites contain a single immunodominant region with two or more identical epitopes. J Exp Med 157:1947-1957. http://dx.doi.org/10.1084/jem.157.6.1947.
9. Zavala F, Tam JP, Hollingdale MR, Cochrane AH, Quakyi I, Nussenzweig RS, Nussenzweig V. 1985. Rationale for development of a synthetic vaccine against Plasmodium falciparum malaria. Science 228:1436-1440. http://dx.doi.org/10.1126/science.2409595.
10. Crompton J, Toogood CI, Wallis N, Hay RT. 1994. Expression of a foreign epitope on the surface of the adenovirus hexon. J Gen Virol 75(Part 1):133-139. http://dx.doi.org/10.1099/0022-1317-75-1-133.
11. Palma C, Overstreet MG, Guedon JM, Hoiczyk E, Ward C, Karen KA, Zavala F, Ketner G. 2011. Adenovirus particles that display the Plasmodium falciparum circumsporozoite protein NANP repeat induce sporozoite-neutralizing antibodies in mice. Vaccine 29:1683-1689. http://dx.doi.org/10.1016/j.vaccine.2010.12.040.
12. Worgall S, Krause A, Rivara M, Hee KK, Vintayen EV, Hackett NR, Roelvink PW, Bruder JT, Wickham TJ, Kovesdi I, Crystal RG. 2005. Protection against P. aeruginosa with an adenovirus vector containing an OprF epitope in the capsid. J Clin Invest 115:1218-1219. http://dx.doi.org/10.1172/JCI200523135.
13. Olotu A, Fegan G, Wambua J, Nyangweso G, Awuondo KO, Leach A, Lievens M, Leboulleux D, Njuguna P, Peshu N, Marsh K, Bejon P. 2013. Four-year efficacy of RTS,S/AS01E and its interaction with malaria exposure. N Engl J Med 368:1111-1120. http://dx.doi.org/10.1056/NEJMoa1207564.
14. White MT, Bejon P, Olotu A, Griffin JT, Riley EM, Kester KE, Ockenhouse CF, Ghani AC. 2013. The relationship between RTS,S vaccineinduced antibodies, CD4(+) T cell responses and protection against Plasmodium falciparum infection. PLoS One 8:e61395. http://dx.doi.org/10.1371/journal.pone.0061395.
15. Agnandji ST, Lell B, Fernandes JF, Abossolo BP, Methogo BG, Kabwende AL, Adegnika AA, Mordmuller B, Issifou S, Kremsner PG, Sacarlal J, Aide P, Lanaspa M, Aponte JJ, Machevo S, Acacio S, Bulo H, Sigauque B, Macete E, Alonso P, Abdulla S, Salim N, Minja R, Mpina M, Ahmed S, Ali AM, Mtoro AT, Hamad AS, Mutani P, Tanner M, Tinto H, D'Alessandro U, Sorgho H, Valea I, Bihoun B, Guiraud I, Kabore B, Sombie O, Guiguemde RT, Ouedraogo JB, Hamel MJ, Kariuki S, Oneko M, Odero C, Otieno K, Awino N, McMorrow M, Muturi-Kioi V, Laserson KF, Slutsker L, Otieno W, Otieno L, et al. 2012. A phase 3 trial of RTS,S/AS01 malaria vaccine in African infants. N Engl J Med 367:2284-2295. http://dx.doi.org/10.1056/NEJMoa1208394.
16. Agnandji ST, Lell B, Soulanoudjingar SS, Fernandes JF, Abossolo BP, Conzelmann C, Methogo BG, Doucka Y, Flamen A, Mordmuller B, Issifou S, Kremsner PG, Sacarlal J, Aide P, Lanaspa M, Aponte JJ, Nhamuave A, Quelhas D, Bassat Q, Mandjate S, Macete E, Alonso P, Abdulla S, Salim N, Juma O, Shomari M, Shubis K, Machera F, Hamad AS, Minja R, Mtoro A, Sykes A, Ahmed S, Urassa AM, Ali AM, Mwangoka G, Tanner M, Tinto H, D'Alessandro U, Sorgho H, Valea I, Tahita MC, Kabore W, Ouedraogo S, Sandrine Y, Guiguemde RT, Ouedraogo JB, Hamel MJ, Kariuki S, Odero C, et al. 2011. First results of phase 3 trial of RTS,S/AS01 malaria vaccine in African children. N Engl J Med 365:1863-1875. http://dx.doi.org/10.1056/NEJMoa1102287.
17. Shiratsuchi T, Rai U, Krause A, Worgall S, Tsuji M. 2010. Replacing adenoviral vector HVR1 with a malaria B cell epitope improves immunogenicity and circumvents preexisting immunity to adenovirus in mice. J Clin Invest 120:3688-3701. http://dx.doi.org/10.1172/JCI39812.
18. Buge SL, Richardson E, Alipanah S, Markham P, Cheng S, Kalyan N, Miller CJ, Lubeck M, Udem S, Eldridge J, Robert-Guroff M. 1997. An adenovirus-simian immunodeficiency virus env vaccine elicits humoral, cellular, and mucosal immune responses in rhesus macaques and decreases viral burden following vaginal challenge. J Virol 71:8531-8541.
19. Klessig DF, Grodzicker T. 1979. Mutations that allow human Ad2 and Ad5 to express late genes in monkey cells map in the viral gene encoding the 72K DNA binding protein. Cell 17:957-966.
20. Hoti N, Li Y, Chen CL, Chowdhury WH, Johns DC, Xia Q, Kabul A, Hsieh JT, Berg M, Ketner G, Lupold SE, Rodriguez R. 2007. Androgen receptor attenuation of Ad5 replication: implications for the development of conditionally replication competent adenoviruses. Mol Ther 15:1495-1503. http://dx.doi.org/10.1038/sj.mt.6300223.
21. Ketner G, Boyer J. 1998. Isolation, growth, and purification of defective adenovirus deletion mutants, p 19-28. In Wold WSM (ed), Adenovirus methods and protocols. The Humana Press Inc., Totowa, NJ.
22. Mittereder N, March KL, Trapnell BC. 1996. Evaluation of the concentration and bioactivity of adenovirus vectors for gene therapy. J Virol 70:7498-7509.
23. Persson C, Oliveira AG, Sultan AA, Bhanot P, Nussenzweig V, Nardin E. 2002. Cutting edge: a new tool to evaluate human pre-erythrocytic malaria vaccines: rodent parasites bearing a hybrid Plasmodium falciparum circumsporozoite protein. J Immunol 169:6681-6685. http://dx.doi.org/10.4049/jimmunol.169.12.6681.
24. Mercier GT, Nehete PN, Passeri MF, Nehete BN, Weaver EA, Templeton NS, Schluns K, Buchl SS, Sastry KJ, Barry MA. 2007. Oral immunization of rhesus macaques with adenoviral HIV vaccines using enteric-coated capsules. Vaccine 25:8687-8701. http://dx.doi.org/10.1016/j.vaccine.2007.10.030.
25. Nardin EH, Nussenzweig V, Nussenzweig RS, Collins WE, Harinasuta KT, Tapchaisri P, Chomcharn Y. 1982. Circumsporozoite proteins of human malaria parasites Plasmodium falciparum and Plasmodium vivax. J Exp Med 156:20-30. http://dx.doi.org/10.1084/jem.156.1.20.
26. Andrade F, Bull HG, Thornberry NA, Ketner GW, Casciola-Rosen LA, Rosen A. 2001. Adenovirus L4-100K assembly protein is a granzyme B substrate that potently inhibits granzyme B-mediated cell death. Immunity 14:751-761. http://dx.doi.org/10.1016/S1074-7613(01)00149-2.
27. Mota MM, Pradel G, Vanderberg JP, Hafalla JC, Frevert U, Nussenzweig RS, Nussenzweig V, Rodriguez A. 2001. Migration of Plasmodium sporozoites through cells before infection. Science 291:141-144. http://dx.doi.org/10.1126/science.291.5501.141.
28. Mishra S, Nussenzweig RS, Nussenzweig V. 2012. Antibodies to Plasmodium circumsporozoite protein (CSP) inhibit sporozoite's cell traversal activity. J Immunol Methods 377:47-52. http://dx.doi.org/10.1016/j.jim.2012.01.009.
29. Lim PL, Tan W, Latchoumycandane C, Mok WC, Khoo YM, Lee HS, Sattabongkot J, Beerheide W, Lim SG, Tan TM, Boelsterli UA. 2007. Molecular and functional characterization of drug-metabolizing enzymes and transporter expression in the novel spontaneously immortalized human hepatocyte line HC-04. Toxicol In Vitro 21:1390-1401. http://dx.doi.org/10.1016/j.tiv.2007.05.003.
30. Chomczynski P, Sacchi N. 1987. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 162:156-159. http://dx.doi.org/10.1016/0003-2697(87)90021-2.
31. Bruna-Romero O, Hafalla JC, Gonzalez-Aseguinolaza G, Sano G, Tsuji M, Zavala F. 2001. Detection of malaria liver-stages in mice infected through the bite of a single Anopheles mosquito using a highly sensitive real-time PCR. Int J Parasitol 31:1499-1502. http://dx.doi.org/10.1016/S0020-7519(01)00265-X.
32. Hollingdale MR, Nardin EH, Tharavanij S, Schwartz AL, Nussenzweig RS. 1984. Inhibition of entry of Plasmodium falciparum and P. vivax sporozoites into cultured cells; an in vitro assay of protective antibodies. J Immunol 132:909-913.
33. Collins, WE. 1992. South American monkeys in the development and testing of malarial vaccines-a review. Mem Inst Oswaldo Cruz 87(Suppl 3):401-406. http://dx.doi.org/10.1590/S0074-02761992000700068.
34. Collins WE, Sullivan JS, Williams A, Nace D, Williams T, Galland GG, Barnwell JW. 2006. Aotus nancymaae as a potential model for the testing of anti-sporozoite and liver stage vaccines against Plasmodium falciparum. Am J Trop Med Hyg 74:422-424.
35. Krause A, Joh JH, Hackett NR, Roelvink PW, Bruder JT, Wickham TJ, Kovesdi I, Crystal RG, Worgall S. 2006. Epitopes expressed in different adenovirus capsid proteins induce different levels of epitope-specific immunity. J Virol 80:5523-5530. http://dx.doi.org/10.1128/JVI.02667-05.
36. Berg M, Adams RJ, Gambhira R, Siracusa MC, Scott AL, Roden RB, Ketner G. 2014. Immune responses in macaques to a prototype recombinant adenovirus live oral HPV16 vaccine. Clin Vaccine Immunol 21: 1224-1231. http://dx.doi.org/10.1128/CVI.00197-14.